Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors

计划入组 50 人 · 首次发布于 2022 年 8 月 4 日

Clinical Features and Outcomes of CBP Versus Non-CBP in Septic Children

计划入组 90 人 · 首次发布于 2021 年 3 月 12 日

Prulifloxacin in Chronic Bacterial Prostatitis (CBP)

计划入组 168 人 · 首次发布于 2017 年 6 月 28 日

Inobrodib

Cbp/p300 degrader (cancer)

CBP/p300 Program(Proteovant Therapeutics)

Check-Cap

CMP Therapeutics Ltd.

United Kingdom

CMP Development LLC

United States

Astex Pharmaceuticals Highlights Preclinical and Clinical Advances at EORTC-NCI-AACR Symposium

CellCentric Secures $120 Million Series C Funding to Advance Oral Multiple Myeloma Treatment

First-in-Class CBP/p300 Inhibitor TT125-802 Shows Promise in Treatment-Resistant NSCLC